Commentary Open Access
Volume 2 | Issue 1 | DOI: https://doi.org/10.46439/ophthalmology.2.009
The GSK3β pathway in optic nerve regeneration
Zubair Ahmed1,*
- 1Neuroscience and Ophthalmology, Institute of Inflammation and Ageing, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK
Corresponding Author
Zubair Ahmed, z.ahmed.1@bham.ac.uk
Received Date: April 09, 2020
Accepted Date: April 21, 2020
Ahmed Z. The GSK3β pathway in optic nerve regeneration. Arch Clin Exp Ophthalmol 2020; 2(1).
Copyright: © 2020 Ahmed Z. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
The GSK3β pathway in optic nerve regeneration
Adult neurons in the mammalian central nervous system (CNS) fail to regenerate after injury due to a number of factors including the reduced intrinsic growth capacity together with the hostile environment of the injured CNS microenvironment [1-4]. However recent studies have shown that modifying the intrinsic growth capacity through a number of cell signalling pathways can promote regeneration of adult CNS neurons. For example, intrinsic factors such as cyclic adenosine monophosphate (cAMP), mammalian target of rapamycin (mTOR), and the repressors phosphatase and tensin homolog (PTEN) and suppressor of cytokine signalling 3 (SOCS3) promote CNS axon regeneration [5-7].
Non-human primate models and multimodal technologies synergistically drive translational breakthroughs in gene therapy for optic nerve diseases
This commentary systematically examines the pivotal role of non-human primate (NHP) models in advancing gene therapy for optic nerve diseases, alongside the ethical and practical challenges they face. It highlights how synergistic innovations in artificial intelligence (AI), organoid technology, CRISPR-based gene editing, and novel delivery systems are reshaping translational paradigms.